Guides · PeptideU · 9 min read

CJC-1295 vs Growth Hormone: Mechanism and Class Compared

The short answer

CJC-1295 is not growth hormone. It is a synthetic analog of growth hormone-releasing hormone (GHRH) that binds the GHRH receptor on pituitary somatotrophs, whereas growth hormone is a 191-amino-acid pituitary protein that binds the growth hormone receptor on peripheral tissues. One clinical study reported that CJC-1295 activated the GH/IGF-1 axis and altered serum protein profiles in normal adults (PMID 19386527). The two sit in different pharmacological classes, have different regulatory status, and are detected by different analytical methods.

The short answer: different classes, linked axis

CJC-1295 and human growth hormone (hGH, somatropin) are frequently discussed together because both are associated with the growth hormone/insulin-like growth factor-1 (GH/IGF-1) axis. They are not, however, the same class of molecule. Growth hormone is the hormone itself. CJC-1295 is an analog of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that instructs the anterior pituitary to release growth hormone. One acts on the pituitary; the other is the product of the pituitary.

That distinction is reflected in the analytical literature, where CJC-1295 is handled as a GHRH analog rather than as a growth hormone preparation: researchers developing immunopurification workflows described methods specifically for growth hormone-releasing hormones prior to liquid chromatography-high resolution mass spectrometry (PMID 32971474), and a separate group reported an antibody-free ultrafiltration assay for growth hormone-releasing hormones in urine at low pg/mL concentrations using nanoLC-HRMS/MS (PMID 35298973). This page compares the two on mechanism, structure, receptor target, regulatory status and the shape of the published evidence. It does not rank them and does not frame either as an option to pursue.

This page is for educational purposes only and is not medical advice; consult a licensed physician about any medical question or any compound discussed here.

Structure and molecular class

Human growth hormone is a single-chain protein of 191 amino acids, roughly 22 kDa, synthesised by somatotroph cells of the anterior pituitary and produced pharmaceutically as recombinant somatropin. CJC-1295 is a much smaller synthetic peptide built on the biologically active N-terminal fragment of GHRH, with amino acid substitutions intended to resist enzymatic degradation; the published pharmacology literature characterises it as a long-acting GHRH analog, and a clinical study using that description reported activation of the GH/IGF-1 axis with accompanying serum protein profile changes in normal adult subjects (PMID 19386527).

The size gap has practical consequences for laboratories. A 2024 method paper described chromatographic-mass spectrometric analysis of peptidic analytes in the 2-10 kDa range in doping control urine samples (PMID 38197510), a window that captures GHRH-sized peptides rather than the larger intact growth hormone protein. Confirmation work has also been published outside human sport: researchers described an LC-MS/MS method for confirming CJC-1295 abuse in equine plasma samples (PMID 30938069), and a later report described detection of CJC-1295 in equine plasma by ELISA (PMID 42876013).

Receptor targets

The clearest separation between the two is the receptor each engages.

Growth hormone binds the growth hormone receptor, a cytokine-family receptor expressed on hepatocytes, adipocytes, chondrocytes and other peripheral tissues, driving JAK/STAT signalling and hepatic IGF-1 output.
CJC-1295, as a GHRH analog, targets the GHRH receptor, a class B G protein-coupled receptor on pituitary somatotrophs; engagement of that upstream step is what produced the GH/IGF-1 axis activation and serum protein changes reported in normal adults (PMID 19386527).

A third receptor is often confused with both: the growth hormone secretagogue receptor (GHS-R), the ghrelin receptor targeted by secretagogues such as the GHRP family. GHS-R is pharmacologically distinct from the GHRH receptor, and it has been used as a molecular recognition element in unrelated analytical chemistry, one 2022 study used affinity interaction with the growth hormone secretagogue receptor for early detection of cannabinoids in biological samples (PMID 34736642). CJC-1295 is not a GHS-R ligand, which is why the literature groups it with GHRH analogs rather than with ghrelin-receptor secretagogues.

Doing the math on a vial? The PeptideU app does reconstitution, units and dilution for you.

Try it free

Side-by-side comparison

Attribute	CJC-1295	Growth hormone (somatropin)
Class	Synthetic GHRH analog, described in the literature as long-acting (PMID 19386527)	Recombinant 191-amino-acid pituitary protein hormone
Primary receptor	GHRH receptor on anterior pituitary somatotrophs	Growth hormone receptor on liver, fat, muscle, bone
Site of first action	Pituitary (upstream)	Peripheral tissues (downstream)
Requires intact pituitary	Yes, acts by stimulating endogenous somatotrophs	No, supplies the hormone directly
Documented axis effect	Activation of the GH/IGF-1 axis with serum protein profile changes reported in normal adults (PMID 19386527)	Hormone replacement in approved deficiency indications
Regulatory status	No approved human medicinal product; appears in research and anti-doping contexts (PMID 42160466)	Approved prescription products for defined endocrine indications
Analytical approach	GHRH-analog assays, including immunopurification-LC-HRMS (PMID 32971474) and urinary nanoLC-HRMS/MS (PMID 35298973)	Protein-hormone and biomarker testing strategies

Is CJC-1295 "a form of HGH"?

No. A GHRH analog and growth hormone are distinct chemical entities with distinct receptors, and the published record treats them separately. Critical reviews of peptide and peptide-analog drugs used in recreational and professional sport and bodybuilding have grouped GHRH analogs such as CJC-1295 under growth hormone secretagogues and releasing factors rather than under growth hormone preparations themselves (PMID 41880199). A structured narrative review of injectable peptides in sports medicine likewise addressed evidence, safety and anti-doping implications for these compounds as a category separate from established hormone therapies (PMID 42160466).

The functional overlap is real but indirect: because GHRH-receptor activation at the pituitary ultimately raises circulating growth hormone and hepatic IGF-1, the measurable downstream readouts can resemble one another. The study in normal adult subjects reported that CJC-1295 activated the GH/IGF-1 axis and produced serum protein profile changes (PMID 19386527). What that means mechanistically is amplification of an endogenous secretory pathway that remains subject to pituitary capacity and feedback, rather than direct delivery of the hormone.

Why the upstream/downstream distinction matters in the literature

Pituitary dependence. A GHRH-receptor agonist can only act where functioning somatotrophs exist; exogenous growth hormone does not share that constraint.
Analytical signature. Detection strategies differ by molecular size and chemistry, which is why GHRH-specific sample preparation has been developed, including magnetic-bead immunopurification compared across surface functionalities (PMID 32971474).
Regulatory framing. Reviews of injectable peptides in sports medicine have discussed anti-doping implications specifically for research-grade peptides lacking approved human products (PMID 42160466).

Tracking research? Log entries with dates, lots and notes — records, never plans.

Get the app

Regulatory status compared

Recombinant human growth hormone is marketed as approved prescription medicines for defined endocrine indications and is dispensed under physician supervision. CJC-1295 has no equivalent approved human product; material circulating under that name is typically labelled research-use-only. Published reviews have repeatedly situated such peptides in a grey zone between research chemistry and consumer use: a narrative review of peptide supplements and their therapeutic applications in sports medicine examined the gap between marketing claims and controlled evidence (PMID 42578445), and a critical review of peptide and peptide-analog drugs in sport described their spread in recreational and professional settings (PMID 41880199).

Anti-doping science has moved in parallel. Beyond human testing, the veterinary literature documented confirmation of CJC-1295 abuse in equine plasma by LC-MS/MS (PMID 30938069) and, more recently, an ELISA-based detection approach in equine plasma (PMID 42876013). The existence of dedicated confirmation assays indicates the compound is treated as a controlled substance within sport rather than as a therapeutic equivalent of growth hormone.

Adverse Events and Safety Signals: What Studies Report

Direct head-to-head safety comparisons between CJC-1295 and growth hormone were not identified in the verified literature set, and the human clinical record for CJC-1295 is limited. The clinical study in normal adult subjects reported activation of the GH/IGF-1 axis together with changes in serum protein profiles (PMID 19386527), which is a pharmacodynamic observation rather than a long-term safety dataset.

Review-level sources have emphasised uncertainty. A structured narrative review of injectable peptides in sports medicine assessed evidence, safety and anti-doping implications and highlighted the limited controlled data supporting widely promoted uses (PMID 42160466). A review of peptide supplements in sports medicine similarly examined therapeutic applications against the available evidence base (PMID 42578445). In gerontology, a 2026 review of therapeutic peptides discussed mechanisms and applications for healthy aging, including agents acting on hormonal axes (PMID 42021992), while a narrative review in urology and sexual medicine covered clinical effectiveness, indications and safety across peptide classes (PMID 42862021). Reviews of peptide use in sport have also flagged unregulated supply and unverified composition as recurring concerns (PMID 41880199).

Want the full course? Every compound, evidence-graded and cited, inside PeptideU.

Start learning free

What the evidence base does and does not contain

Readers comparing the two classes should note the asymmetry in evidence volume. Growth hormone has decades of registrational trial data behind approved indications. For CJC-1295, the identified human clinical evidence centres on axis activation and serum protein profiling in normal adults (PMID 19386527), while much of the remaining literature is analytical chemistry and anti-doping methodology (PMID 38197510, PMID 35298973) or narrative review (PMID 42160466). No comparative efficacy trial between CJC-1295 and recombinant growth hormone appears in the verified set, so claims that one outperforms the other are not supported by the sources summarised here.

References

Frequently asked questions

Is CJC-1295 the same thing as HGH?▾

No. Growth hormone is a 191-amino-acid pituitary protein, while CJC-1295 is a much smaller synthetic analog of growth hormone-releasing hormone. A clinical study described CJC-1295 as a long-acting GHRH analog and reported that it activated the GH/IGF-1 axis with serum protein profile changes in normal adult subjects (PMID 19386527). They are separate chemical classes with separate receptors.

Which receptor does each compound bind?▾

Growth hormone binds the growth hormone receptor on peripheral tissues such as liver, fat and muscle. CJC-1295, as a GHRH analog, targets the GHRH receptor on pituitary somatotrophs; researchers reported that this upstream action activated the GH/IGF-1 axis in normal adults (PMID 19386527). The separate ghrelin receptor, GHS-R, has been used in unrelated analytical work (PMID 34736642).

Do head-to-head trials compare CJC-1295 with growth hormone?▾

No comparative efficacy trial appears in the literature summarised here. The identified human clinical evidence for CJC-1295 centres on GH/IGF-1 axis activation and serum protein profiling in normal adults (PMID 19386527), while review-level sources have emphasised limited controlled data for injectable peptides used in sports medicine (PMID 42160466). No study in this set ranks one against the other.

How is CJC-1295 detected in anti-doping testing?▾

Analytical groups have built methods specific to GHRH analogs. Researchers compared magnetic bead surface functionalities for immunopurification of growth hormone-releasing hormones before LC-high resolution mass spectrometry (PMID 32971474), and a separate team reported an antibody-free ultrafiltration assay detecting these peptides in urine at low pg/mL concentrations (PMID 35298973). Equine plasma methods have also been published (PMID 30938069).

What is the regulatory difference between the two?▾

Recombinant human growth hormone is sold as approved prescription medicine for defined endocrine indications. CJC-1295 has no equivalent approved human product and is generally labelled research-use-only. Reviews of peptide and peptide-analog drugs in sport have described this unregulated space and its anti-doping implications (PMID 41880199, PMID 42160466). This page is educational and is not medical or legal advice.

What do reviews report about safety signals for GHRH analogs?▾

Long-term human safety data are limited. A structured narrative review of injectable peptides in sports medicine assessed evidence, safety and anti-doping implications and noted sparse controlled data (PMID 42160466), while a review of peptide supplements examined therapeutic claims against the available evidence (PMID 42578445). A gerontology review also discussed peptides acting on hormonal axes (PMID 42021992).

Why do the two produce overlapping downstream readouts?▾

Because GHRH-receptor activation at the pituitary ultimately raises circulating growth hormone and hepatic IGF-1, measurable markers can look similar. The study in normal adult subjects reported axis activation and serum protein profile changes after CJC-1295 (PMID 19386527). That reflects amplification of an endogenous secretory pathway, which still depends on pituitary capacity, rather than direct hormone delivery.

The PeptideU app

Track it. Calculate it. Actually understand it.

Research trackerLog every entry with dates, lots and notes — records, never plans.

CalculatorsReconstitution, units and dilution maths without the guesswork.

The UniversityEvery compound explained, evidence-graded, cited to the literature.

Get started freePeptideU Premium — $9.99/mo for the full curriculum, advanced tracking & giveaways

Download on theApp Store — Free Get it onGoogle Play

References

Keep learning

18+ · Educational purposes only
This page summarises published research for education — it is not medical advice, and nothing here is a recommendation to use, purchase, or dose any substance. Study parameters described are what researchers reported, not instructions. Consult a qualified clinician before any health decision.